Fifth Third Wealth Advisors LLC Invests $225,000 in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Fifth Third Wealth Advisors LLC purchased a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 4,296 shares of the biopharmaceutical company’s stock, valued at approximately $225,000.

A number of other institutional investors have also recently added to or reduced their stakes in HALO. GAMMA Investing LLC raised its position in Halozyme Therapeutics by 96.6% in the second quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 254 shares during the period. Fifth Third Bancorp raised its position in Halozyme Therapeutics by 2.4% in the second quarter. Fifth Third Bancorp now owns 11,206 shares of the biopharmaceutical company’s stock valued at $587,000 after purchasing an additional 261 shares during the period. First Horizon Advisors Inc. raised its position in Halozyme Therapeutics by 24.5% in the fourth quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 293 shares during the period. FCF Advisors LLC raised its holdings in shares of Halozyme Therapeutics by 1.9% in the 1st quarter. FCF Advisors LLC now owns 21,164 shares of the biopharmaceutical company’s stock valued at $861,000 after buying an additional 391 shares during the period. Finally, New York State Teachers Retirement System raised its holdings in shares of Halozyme Therapeutics by 0.4% in the 1st quarter. New York State Teachers Retirement System now owns 113,820 shares of the biopharmaceutical company’s stock valued at $4,630,000 after buying an additional 400 shares during the period. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. The Goldman Sachs Group boosted their target price on Halozyme Therapeutics from $44.00 to $49.00 and gave the stock a “neutral” rating in a research note on Monday, July 22nd. Benchmark reissued a “buy” rating and issued a $60.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, August 8th. JPMorgan Chase & Co. decreased their price target on shares of Halozyme Therapeutics from $53.00 to $52.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Piper Sandler lowered shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their price objective for the company from $48.00 to $51.00 in a research note on Friday, June 7th. Finally, Wells Fargo & Company boosted their price target on Halozyme Therapeutics from $48.00 to $58.00 and gave the company an “overweight” rating in a research report on Friday, June 7th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $59.44.

Halozyme Therapeutics Trading Down 0.9 %

Shares of Halozyme Therapeutics stock opened at $61.64 on Friday. The company has a 50-day moving average of $54.23 and a two-hundred day moving average of $45.60. The stock has a market cap of $7.85 billion, a PE ratio of 25.47, a price-to-earnings-growth ratio of 0.56 and a beta of 1.27. The company has a current ratio of 6.64, a quick ratio of 5.36 and a debt-to-equity ratio of 8.44. Halozyme Therapeutics, Inc. has a 12-month low of $32.83 and a 12-month high of $62.58.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.18. Halozyme Therapeutics had a return on equity of 225.71% and a net margin of 36.94%. The company had revenue of $231.40 million for the quarter, compared to the consensus estimate of $204.94 million. During the same period in the previous year, the business earned $0.68 earnings per share. Halozyme Therapeutics’s quarterly revenue was up 4.7% compared to the same quarter last year. On average, research analysts anticipate that Halozyme Therapeutics, Inc. will post 3.66 EPS for the current fiscal year.

Insider Buying and Selling at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $61.75, for a total value of $617,500.00. Following the sale, the senior vice president now directly owns 168,176 shares in the company, valued at $10,384,868. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Halozyme Therapeutics news, CFO Nicole Labrosse sold 5,000 shares of the company’s stock in a transaction dated Monday, July 22nd. The shares were sold at an average price of $53.93, for a total value of $269,650.00. Following the transaction, the chief financial officer now directly owns 15,480 shares in the company, valued at approximately $834,836.40. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $61.75, for a total transaction of $617,500.00. Following the sale, the senior vice president now owns 168,176 shares of the company’s stock, valued at $10,384,868. The disclosure for this sale can be found here. In the last three months, insiders sold 64,881 shares of company stock worth $3,585,084. 2.40% of the stock is owned by corporate insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.